More Articles

Perceptions of biosimilars among US cancer patients Biosimilars/Research | Posted 30/08/2019

Amid increasingly expensive cancer treatments, researchers in the US explored perceptions of generic drugs among a group of 75 patients, in findings presented alongside the 2019 American Society of...

Heparin biosimilar to be marketed in Canada Biosimilars/News | Posted 30/08/2019

Canadian pharmaceuticals firm Valeo Pharma Inc has been given the rights to market a biosimilar version of low molecular weight heparin (LMWH), which is used to prevent blood clots in a range of co...

Momenta drops Humira biosimilar development Biosimilars/General | Posted 30/08/2019

Momenta Pharmaceuticals Inc announced its financial results for the second quarter of 2019 on 2 August 2019. In this, they reported that they will stop the development of their Humira (adalimumab)....

China issues list of generics needed in the country Generics/General | Posted 30/08/2019

Authorities in China have introduced an initiative which the country hopes will boost the development of generics by encouraging pharmaceutical companies to develop and produce them.

Alvotech and Cipla Gulf partnership announced Pharma News | Posted 30/08/2019

On 29 July 2019, pharmaceutical companies Alvotech and Cipla Gulf announced that they have entered into an exclusive partnership for the commercialization of an adalimumab biosimilar (AVT02), in a...

Comparison of darbepoetin alfa and epoetin alfa for the treatment of renal anaemia Biosimilars/Research | Posted 30/08/2019

Darbepoetin alfa (DA-α) manufactured by Hetero Biopharma (Hetero) is the first long-acting erythropoiesis-stimulating agent with extended dosing intervals. This gives it an advantage over epoetin a...

Patent challenges in the SADC region Generics/Research | Posted 30/08/2019

High pharmaceutical prices restrict access to essential medicines. New medicines are often patent protected which sustains prices well above the cost of production. This problem was particularly ap...

Trastuzumab biosimilar to be distributed by Mundipharma Biosimilars/News | Posted 30/08/2019

Singapore-based Prestige BioPharma’s (Prestige) trastuzumab biosimilar Tuznue (HD201) will be distributed in selected European markets exclusively by UK-based Mundipharma International (Mundipharma...